Τίτλος:
B2 microglobulin: Is it a reliable marker of activity in inflammatory
bowel disease?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
OBJECTIVES: The aims of this study were to investigate a possible
positive correlation between B2-microglobulin (B2-M) serum levels and
the severity and activity of inflammatory bowel disease (IBD); and to
examine whether B2-M levels reflect IBD extent.
METHODS: We examined B2-M serum levels in 87 ulcerative colitis (UC)
patients, 74 with Crohn’s disease (CD) and 68 control subjects, using an
enzymatic method. The reliability of the measuring method was assessed
by evaluating serum B2-M in 18 patients suffering from chronic renal
failure (CRF). The severity and activity of IBD was estimated using the
van Hees Activity Index and the True-love-Witts criteria for CD and UC
patients respectively. Endoscopic evaluation for UC patients was done
according to Baron’s et nl. classification; Riley’s et al. criteria were
used for histological evaluation.
RESULTS: B2-M serum levels were significantly increased in all CD
patients except those in remission. After 6 months treatment a second
blood sample taken from CD patients with initially elevated B2-M levels
proved to be compatible with CD severity at that time. Such a positive
correlation was not assessed in UC patients; therefore, a second blood
sample was considered unnecessary. Furthermore, CD patients with
pancolitis, ileal-caecal, or small intestinal disease had higher B2-M
levels than those with left-sided, anal, or perianal disease.
CONCLUSIONS: B2-M serum levels could prove to be a useful marker in
assessing not only the activity, severity, and extent of CD but the
treatment efficacy as well. (C) 2001 by Am. Cell. of Gastroenterology.
Συγγραφείς:
Zissis, M
Afroudakis, A
Galanopoulos, G
Palermos, I and
Boura, X
Michopoulos, S
Archimandritis, A
Περιοδικό:
The American Journal of Gastroenterology
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/S0002-9270(01)02444-3
